Zhejiang Taimei Medical Technology Co Ltd Class H
HHKEX:25764.26
HKD
-0.19
(-4.27%)
ISIN
CNE100006M66
Return %
Stock
S&P 500
1Y
1.43
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Yun Yun Wan
- Full Time Employees
- 687
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Building 9 Jiaxing ZH China 314000
- IPO Date
- Oct 8, 2024
- Website
- taimei.com
- Similar Companies
- Business
- Zhejiang Taimei Medical Technology Co., Ltd. (2576.HK) is a China-based medical device company specializing in the research, development, manufacture, and sale of advanced medical equipment and consumables. The company offers a comprehensive portfolio of products including cardiovascular intervention devices such as drug-coated balloons, drug-eluting stents, and percutaneous transluminal angioplasty balloons; peripheral vascular intervention products like guidewires, introducer sheaths, and vascular access closure devices; neurovascular intervention tools including aspiration catheters and stent retrievers; and orthopedic medical devices such as spinal internal fixation systems and joint prostheses. Taimei Medical also provides cardiac rhythm management solutions, including pacemakers and defibrillators, alongside diagnostic imaging equipment and surgical robots; these offerings target hospitals, clinics, and healthcare providers primarily in China, with expanding operations into Southeast Asia, Europe, and North America. Founded in 2013 and headquartered in Haining, Zhejiang Province, the company operates through subsidiaries focused on R&D and international distribution. In recent developments, Taimei Medical completed its initial public offering on the Hong Kong Stock Exchange in July 2024, raising approximately HKD 1.02 billion to fund R&D expansion, manufacturing capacity upgrades, and global market penetration. The company formed a strategic partnership with a leading European medical device distributor in early 2025 to accelerate penetration into the EU market and launched its next-generation drug-eluting stent platform, Taimei DES-II, which received NMPA approval in China in October 2025, featuring improved biocompatibility and reduced restenosis rates. Additionally, Taimei acquired a minority stake in a U.S.-based neurovascular startup in September 2025 to bolster its pipeline in minimally invasive stroke treatments, while expanding its production facility in Zhejiang by 50% to meet rising domestic demand amid China's aging population.